Injection of denosumab-qbde biosimilar (Enoby/Xtrenbo), billed per 1 milligram

This code represents a biosimilar to denosumab (reference product: Prolia or Xgeva), specifically the product marketed as Enoby or Xtrenbo, billed per 1 mg. Denosumab is a RANK ligand inhibitor that reduces osteoclast activity, used to treat bone loss and skeletal-related events. As a biosimilar, this product has been FDA-approved as highly similar to the reference biologic with no clinically meaningful differences.

Use this code when the biosimilar denosumab-qbde (Enoby/Xtrenbo) is administered—not when the reference product (Prolia/Xgeva) or another denosumab biosimilar is dispensed. Applicable clinical scenarios include treatment of osteoporosis in postmenopausal women or men at high fracture risk, bone loss associated with hormone ablation therapy, and prevention of skeletal-related events in patients with bone metastases from solid tumors. Documentation should confirm the specific product name, lot number, NDC, and administered dose in milligrams.

• Dose-based billing: Denosumab dosing varies significantly by indication (60 mg for osteoporosis vs. 120 mg for bone metastases); verify the total mg administered and bill units accordingly, as each unit represents 1 mg.
• Biosimilar specificity: Do not interchange with codes for reference denosumab (J0897 for Prolia/Xgeva) or other denosumab biosimilars—payers require the code that matches the exact product dispensed, confirmed by NDC.
• Payer and interchangeability considerations: Some payers may require prior authorization or step therapy documentation confirming medical necessity for the biosimilar; verify whether the payer follows FDA interchangeability designations when substitution occurs at the pharmacy level.